OnKure Therapeutics, Inc.

For the period ended Mar 31, 2026. Filed May 5, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 5, 2026

OKUR$3.19+11.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and per share data)

	March 31,	December 31,
	2026	2025
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$192,106	$59,050
Prepaid expenses and other current assets	5,376	1,789
Total current assets	197,482	60,839
Property and equipment, net	519	618
Operating lease right-of-use asset	288	387
Other assets	405	273
Total assets	$198,694	$62,117
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$11,022	$1,433
Accrued expenses and other current liabilities	2,898	3,939
Operating lease liabilities, current portion	409	549
Total current liabilities	14,329	5,921
Other long-term liabilities	12	12
Total liabilities	14,341	5,933
Commitments and contingencies
Stockholders’ equity:
Common stock, Class A, $0.0001 par value; 200,000,000 shares authorized; 40,395,480 and 13,673,565 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively	4	1
Common stock, Class B, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2026 and December 31, 2025	—	—
Additional paid-in capital	413,747	270,424
Accumulated deficit	(229,398)	(214,241)
Total stockholders’ equity	184,353	56,184
Total liabilities and stockholders’ equity	$198,694	$62,117

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.